1. Research progress on the association of insulin resistance with type 2 diabetes mellitus and Alzheimer's disease.
- Author
-
Zheng M, Wang C, Hu M, Li Q, Li J, Quan S, Zhang X, and Gu L
- Subjects
- Humans, Animals, Brain metabolism, Hypoglycemic Agents therapeutic use, Hypoglycemic Agents pharmacology, Signal Transduction physiology, Insulin metabolism, Alzheimer Disease metabolism, Diabetes Mellitus, Type 2 metabolism, Insulin Resistance physiology
- Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that is characterized by insulin resistance and hyperglycemia. It is also known to be a risk factor for Alzheimer's disease (AD). Insulin plays a crucial role in regulating the body's metabolism and is responsible for activating the Phosphoinotide-3-Kinase (PI3K)/Protein Kinase B (Akt) signaling pathway. This pathway is activated when insulin binds to the insulin receptor on nerve cells, and it helps regulate the metabolism of glucose and lipids. Dysfunction in the insulin signaling pathway can lead to a decrease in brain insulin levels and insulin sensitivity, thereby inducing disruptions in insulin signal transduction and leading to disorders in brain energy metabolism. Moreover, these dysfunctions also contribute to the accumulation of β-amyloid (Aβ) deposition and the hyperphosphorylation of Tau protein, both of which are characteristic features of AD. Therefore, this article focuses on insulin resistance to reveal the complex mechanism between brain insulin resistance and AD occurrence in T2DM. On this basis, this article further summarizes the biological effects and mechanisms of antidiabetic drugs on the two diseases, aiming to provide new ideas for the discovery of drugs for the treatment of T2DM combined with AD., Competing Interests: Declarations. Ethics approval and consent to participate: This article does not contain any studies with human participants or animals performed by any of the authors. Consent for publication: All of the authors consent for publication. Competing interests: The authors declare no competing interests. Abbreviations: T2DM Type 2 diabetes mellitus AD Alzheimer’s disease PI3K Phosphoinotide-3-Kinase Akt Protein Kinase B Aβ β-amyloid PTK Protein Tyrosine Kinase SH2 Src homology domain 2 GLUT4 glucose transporter 4 GSK-3 glycogen synthase kinase-3 IRS insulin receptor substrates GS Glycogen synthetase FOXO1 forkhead box O1 CREB cAMP-response elementbinding FFA Free Fatty Acid TNF-α Tumor Necrosis Factor-α IL-6 Interleukin-6 IL-1β Interleukin-1β CRP C-reactive Protein PKC Protein kinase C DAG diacylglycerol JNK c-jun N-terminal kinase BBB blood-brain barrier NFT neurofibrillary tangles IDE insulin degrading enzymes IGF insulin-like growth factor ChAT choline acetyltransferase ApoE apolipoprotein E BACE1 Beta-secretase 1 APP amyloid precursor protein GLP-1 Glucagon-like peptide-1 TZD Thiazolidinediones PPARs peroxisome proliferator-activated receptor gamma DPP-4 Dipeptidyl-peptidase IV GIP glucose-dependent insulinotropic peptide HFD high-fat diet, (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF